PD 168568

PD 168568 is a orally active and potent dopamine receptor D4 (DRD4) antagonist. PD 168568 contains an isoindolinone and is selective for the D4 receptor versus D2 and D3, with Ki values of 8.8, 1842, and 2682 nM, respectively. PD 168568 can be used for glioblastoma (GBM) research[1][2].

Product Specifications

CAS Number

[210688-56-5]

UNSPSC

12352005

Target

Dopamine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Cancer-programmed cell death

Field of Research

Cancer; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/pd-168568.html

Solubility

10 mM in DMSO

Smiles

O=C1NC(CCN2CCN(C3=CC=C(C)C(C)=C3)CC2)C4=C1C=CC=C4

Molecular Formula

C22H27N3O

Molecular Weight

349.47

References & Citations

[1]Dolma S, et al. Inhibition of Dopamine Receptor D4 Impedes Autophagic Flux, Proliferation, and Survival of Glioblastoma Stem Cells. Cancer Cell. 2016 Jun 13;29 (6) :859-873.|[2]Lindsley CW, et al. Return of D4 Dopamine Receptor Antagonists in Drug Discovery. J Med Chem. 2017 Sep 14;60 (17) :7233-7243.|[3]Belliotti TR, et al. Isoindolinone enantiomers having affinity for the dopamine D4 receptor. Bioorg Med Chem Lett. 1998 Jun 16;8 (12) :1499-502.